Azitra (AZTR) Income from Continuing Operations (2022 - 2026)
Azitra's (AZTR) quarterly Income from Continuing Operations came in at 3927240.0 in Q1 2026, down 27.99% YoY from 5453903.56 in Q1 2025, and down 75.83% on a QoQ basis from 2233504.0 in Q4 2025.
Azitra (AZTR) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Income from Continuing Operations data on file, last reported at 3927240.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 27.99% year-over-year to 3927240.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11814265.0 (down 29.78% YoY) and the FY2025 annual result came in at 10955370.0, down 22.17% from the prior year.
- Income from Continuing Operations fell to 3927240.0 in Q1 2026, from 2233504.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1009491.0 in Q3 2024 to a low of 4429528.0 in Q2 2023.
- A 5-year average of 2644066.12 and a median of 2544586.5 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 48.05% — and 2025, when it tumbled 173.85%.
- Tracing AZTR's Income from Continuing Operations over 5 years: stood at 2882439.0 in 2022, then climbed by 14.87% to 2453785.0 in 2023, then climbed by 2.47% to 2393133.0 in 2024, then grew by 6.67% to 2233504.0 in 2025, then sank by 75.83% to 3927240.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3927240.0 (Q1 2026), 2233504.0 (Q4 2025), and 2764528.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | -3.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.35 Mn |
| Mar 31, 2026 | -3.93 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Sep 30, 2025 | -2.76 Mn |
| Jun 30, 2025 | -2.89 Mn |
| Mar 31, 2025 | -3.07 Mn |
| Dec 31, 2024 | -2.39 Mn |
| Sep 30, 2024 | -1.01 Mn |
| Jun 30, 2024 | -2.63 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Dec 31, 2023 | -2.45 Mn |
| Sep 30, 2023 | -1.94 Mn |
| Jun 30, 2023 | -4.43 Mn |
| Mar 31, 2023 | -2.46 Mn |
| Dec 31, 2022 | -2.88 Mn |
| Sep 30, 2022 | -2.40 Mn |
| Jun 30, 2022 | -1.89 Mn |